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When new or continued anticoagulation is necessary
for patients with HAAbs and oral anticoagulation with
warfarin is not appropriate, a nonsensitive heparin form 
of anticoagulation becomes necessary. This anticoagula-
tion could be in the form of nonsensitive low molecular
weight heparins (LMWHs), heparinoids, direct thrombin
inhibitors, and platelet function inhibitors. Lepirudin, a
recombinant form of the medicinal leech salivary protein
hirudin (a direct thrombin inhibitor), was approved by the
US Food and Drug Administration for use in patients with
HIT in March 1998. The purpose of this study was to
determine whether lepirudin is a safe and effective antico-
agulant for patients with HAAbs.
METHODS
Approval from the Institutional Review Board was
obtained before any inquiries. Names of patients who
received lepirudin from September 1, 1998, to March 31,
2000, were obtained from pharmacy records. The pres-
ence of HAAbs in these patients was determined by
reviewing results of platelet aggregation testing for
HAAbs. Only patients who had positive results from a
platelet aggregation test and received lepirudin are
included in this study.
Charts were retrospectively reviewed and analyzed for
the indications for anticoagulation and the duration of
therapy for lepirudin. The effectiveness of anticoagulation
Heparin-induced thrombocytopenia (HIT) occurs in
2% to 4% of patients receiving heparin. This immune disor-
der is associated with a thrombocytopenia caused by the
binding of heparin-associated antiplatelet antibodies
(HAAbs) to platelets in the presence of heparin. Any
patient exposed to heparin is at risk for these antibodies
developing. Patients with multiple exposures to heparin,
especially patients undergoing hemodialysis and multiple
cardiac or vascular procedures, are more likely to have
HAAbs. A patient with HAAbs who is exposed to heparin
may have thrombocytopenia, paradoxical arterial or venous
thromboembolic complications, or resistance to heparin
anticoagulation. The morbidity and mortality of HIT have
been reported as high as 61% and 23% in early studies1 and
as low as 7.4% and 1.1%, respectively, with early recognition
and prompt cessation of heparin administration.2
17
From the Division of Vascular Surgery, Department of Surgery, University
of Missouri Health Care.
Competition of interest: nil.
Presented at the Twenty-fourth Annual Meeting of the Midwestern
Vascular Surgical Society Meeting, Scottsdale, Ariz, Nov 6, 2000.
Reprint requests: Donald Silver, MD, Division of Vascular Surgery,
University of Missouri Health Care, One Hospital Drive, N510,
Columbia, MO 65212 (e-mail: silverd@health.missouri.edu).
Copyright © 2001 by The Society for Vascular Surgery and The American
Association for Vascular Surgery.
0741-5214/2001/$35.00 + 0 24/6/115602
doi:10.1067/mva.2001.115602
Lepirudin is a safe and effective anticoagulant for
patients with heparin-associated antiplatelet
antibodies
Junaid H. Mudaliar, MD, Timothy K. Liem, MD, Walter K. Nichols, MD, Donald P. Spadone, MD, and
Donald Silver, MD, Columbia, Mo
Objective: The purpose of this study was to determine whether lepirudin, a direct thrombin inhibitor, is a safe and effec-
tive anticoagulant for patients with heparin-associated antiplatelet antibodies (HAAbs).
Methods: The charts of HAAb-positive patients who received lepirudin were reviewed. Lepirudin use was analyzed for
indication, duration, and effectiveness of anticoagulation, and for adverse events. HAAb presence was determined by
platelet aggregation.
Results: Eighteen HAAb-positive patients received lepirudin: 9 had previous documentation of HAAb, 6 had throm-
bocytopenia while receiving heparin; and 3 had HAAb after a thrombotic event. The indications for lepirudin antico-
agulation included thromboembolism prophylaxis (5), arterial thromboses (5), pulmonary embolus (3) or deep venous
thrombosis (1), and one each for atrial fibrillation, myocardial infarction, artificial heart valves, and hemodialysis
access. The average duration of therapy was 4.04 days. Fifteen patients achieved adequate anticoagulation (activated
partial thromboplastin time [aPTT] ratio > 2.0) with lepirudin. Seven patients had aPTTs that were sometimes
supratherapeutic (aPTT > 100 seconds) but did not bleed. In all patients who had heparin-induced thrombocytopenia,
platelet counts were normalized while they received lepirudin. There were two complications: one patient fell and had
a calf hematoma (aPTT ratio 3.24), and one patient who received lepirudin during nine separate hospitalizations had
epistaxis (aPTT ratio 2.86) during her ninth hospitalization. Another patient received lepirudin during two hospital-
izations without an adverse event.
Conclusion: Lepirudin is a safe and effective anticoagulant for patients with HAAbs. The platelet counts of all patients
with heparin-induced thrombocytopenia were normalized while they received lepirudin. Careful monitoring of the
aPTT and avoidance of trauma while patients are receiving lepirudin are recommended. (J Vasc Surg 2001;34:17-20.)
was determined with activated partial thromboplastin
times (aPTTs). Effective anticoagulation with lepirudin
was defined as a prolongation of the aPTT to achieve a
ratio 2.0 to 2.5 times the control. The indications for
patients with HAAbs undergoing anticoagulation were
recorded. Laboratory data analyzed included platelet
counts and aPTTs. The patients’ hospital courses were
evaluated for thromboembolic events, hemorrhagic com-
plications, and death.
RESULTS
Twenty-three patients received lepirudin during the
18 months studied. Eighteen of those receiving lepirudin
had HAAbs. One of the five remaining patients had a
platelet thrombus extracted from an occluded dialysis
access graft, one had thrombocytopenia with a right iliac
artery occlusion, and three had a previous history of HIT.
These five patients did not have HAAbs when tested and
were therefore not included in this study.
Seven men and 11 women who were positive for
HAAbs received lepirudin. The mean age was 53 years
(range, 17-86 years). Ten patients had a history of car-
diac disease, five had end-stage renal disease, and 12 had
documented past exposure to heparin during either the
present or a past hospitalization. Seven patients had a
diagnosis of peripheral vascular disease. Nine patients
had hypertension, and nine patients had diabetes melli-
tus. No patient had a history of a venous thromboem-
bolic disorder.
The indication for anticoagulation was established
independently by each patient’s physician. Five patients
received lepirudin as a bolus dose for arterial thrombosis
prophylaxis during surgery or during an invasive cardiac
diagnostic procedure. No patient received lepirudin for
venous throboembolism prophylaxis. Five patients
received lepirudin for arterial thrombosis or lower extrem-
ity critical ischemia. Of these patients, three were treated
with lepirudin in conjunction with thrombolytic therapy
and one patient received lepirudin during an operative
thrombectomy. Three patients received lepirudin for the
early management of a pulmonary embolus and one for
deep venous thrombosis. One of the patients with a pul-
monary embolus also received thrombolytic therapy con-
currently with the lepirudin. One patient each was treated
with lepirudin for myocardial infarction, hemodialysis,
atrial fibrillation, and the presence of an artificial heart
valve. No patient had a thrombotic episode while receiv-
ing lepirudin. None of the three patients (aPPT ratio
1.74-2.80) receiving concomitant thrombolytic therapy
had a bleeding complication.
HAAbs were present in 18 patients. Nine patients had
previous documentation of HIT and HAAbs. Three
patients had thrombotic events and tested positive for
HAAbs during their workups for a hypercoagulable state.
Five patients had thrombocytopenia while receiving
heparin and subsequently tested positive for HAAbs. The
platelet counts dropped to an average of 43.7% (range,
26.8%-55.2% of the preheparin value) and returned to
124% (range, 37%-219%) of the preheparin values at the
end of lepirudin therapy.
The duration of lepirudin therapy ranged from a single
bolus dose to a bolus followed by a continuous intravenous
infusion for 14 days; the mean length of therapy was 4.04
days. Seven patients received lepirudin for 7 or more days.
For patients with normal renal function, the bolus dose was
0.4 mg/kg of lepirudin, and when indicated, it was fol-
lowed by a continuous infusion of 0.15 mg/kg per hour.
The infusion was adjusted to maintain the aPTT ratio
between 2.0 and 2.5. Fifteen patients achieved adequate
anticoagulation with aPTT ratios greater than 2.0. The
three patients who did not achieve therapeutic anticoagula-
tion received lepirudin as a single dose during a heart
catheterization, during surgery for a ruptured femoral
aneurysm, and during surgery for a thrombosed dialysis
access graft. Seven patients treated with lepirudin had
aPTTs that were sometimes supratherapeutic (> 100 sec-
onds) but did not have bleeding complications.
Dosing was decreased in patients with decreased renal
function. Patients with renal insufficiency had the initial
bolus dose halved and the continuous infusion decreased
based on creatinine clearance. Patients with renal failure
needing anticoagulation during dialysis were given boluses
of lepirudin of 0.02 mg/kg.
Two patients received lepirudin during more than one
hospitalization. One patient received lepirudin during
dialysis, in lieu of heparin, during nine different hospital-
izations. This patient had an easily controlled epistaxis
while receiving lepirudin during the ninth hospitalization.
The other patient had artificial heart valves and received
bolus doses of lepirudin on two occasions for thrombosis
prophylaxis. This patient did not achieve therapeutic anti-
coagulation and had no adverse effects.
Adverse events occurred in two patients (11%). One
patient, as mentioned before, had a brief episode of epi-
staxis that was easily controlled. Her aPTT ratio was 2.86 at
the time of the epistaxis. The other patient had a traumatic
calf hematoma after a fall that required operative debride-
ment. Her aPTT ratio was 3.24, indicating an excess of lep-
irudin. Neither patient required a blood transfusion. No
patient had an allergic reaction or thromboembolic event.
Although one of the 18 patients died of systemic lupus ery-
thematosus, no death was related to lepirudin.
DISCUSSION
HAAbs develop in 2% to 4% of patients receiving
heparin, if exposed to the sensitizing heparin, they are at
risk for HIT. HAAbs have been detected in 21% of
patients with peripheral vascular disease undergoing non-
emergency arterial reconstruction. The patients with
HAAbs had a 2.6-fold increase in perioperative throm-
botic events.3 All patients who receive heparin must be
monitored for HIT; their platelet counts must be fol-
lowed. When HIT is suspected (a falling platelet count,
new arterial or venous thromboembolism, or resistance to
anticoagulation with heparin), heparin must be stopped
and the patient tested for HAAbs. If the patient does not
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have HAAbs, heparin may be restarted. If HAAbs are
detected, an alternate anticoagulation must be chosen.
Several agents are available for the rapid anticoagulat-
ing of patients with HAAbs (eg, LMWHs, danaparoid [a
heparinoid], and thrombin inhibitors). All of these agents
offer adequate anticoagulation, and all except the throm-
bin inhibitors may react with each patient’s HAAbs. We
have found the cross-reactivity between LMWHs and
HAAbs from patients receiving unfractionated heparin to
be 34% with enoxaparin4 and 25.5% with dalteparin.5
LMWHs should only be used if studies reveal no cross-
reaction with the patient’s HAAbs. Danaparoid also cross-
reacts with approximately 20% of plasma from patients
with HAAbs.5
Platelet function inhibitors such as aspirin and dipyri-
damole protect patients with HAAbs from thromboem-
bolic complications during brief exposures to heparin, but
not from thrombocytopenia.6 The glycoprotein IIb/IIIa
inhibitor abciximab inhibits HAAb-induced platelet
aggregation,7 but the glycoprotein IIb/IIIa inhibitors
have not been shown to provide adequate anticoagulation
as the sole agent in patients with HAAbs. Certain glyco-
proteins IIb/IIIa inhibitors, such as abciximab, have been
associated with thrombocytopenia and hemorrhagic com-
plications. Thus, patients who are thrombocytopenic may
be placed at an increased risk for bleeding by the glyco-
protein IIb/IIIa inhibitors.8,9
Thrombin inhibitors, such as lepirudin, offer the
patient adequate anticoagulation with no risk of cross-
reaction with their HAAbs. Lepirudin binds to clot-bound
thrombin as well as soluble thrombin. Lepirudin is
excreted by the kidneys so dosage must be reduced in
patients with renal insufficiency; patients undergoing dial-
ysis should receive lepirudin with caution and with
reduced dosage. Lepirudin has a short circulating half-life
of 1.3 hours in patients with normal renal function. The
half-life may be as long as 2 days in patients with advanced
renal failure. Currently, no antidote for lepirudin exists,
but the short half-life in patients with normal renal func-
tion allows for rapid correction of prolonged aPTTs.
Six of the 18 patients in this study had thrombocy-
topenia. The platelet counts of these patients, except for
one patient who had pancytopenia from systemic lupus
erythematosus before heparin therapy, returned to normal
during or after lepirudin therapy. Greinacher et al10 have
reported a series of patients who had a rapid and sustained
recovery of platelet counts with lepirudin therapy. They
reported an increase in platelet counts in 88.7% of the
patients.
Patients who receive lepirudin on multiple occasions
may have an antibody that leads to prolongation of the
aPTT by reducing the rate of excretion of the lepirudin.
Huhle et al11 studied 27 patients with HIT who were
treated with recombinant hirudin for a mean duration of
32 days. The overall incidence of antibodies to recombi-
nant hirudin was 74% with seroconversion, usually occur-
ring after 6 days of treatment. Patients with antibodies had
higher aPTTs than patients without antibodies.
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In our study, only two patients received lepirudin on
multiple occasions, whereas seven patients received lep-
irudin for more than 6 days. Of these nine patients, three
achieved supratherapeutic anticoagulation. Only one of
the nine patients had a hemorrhagic complication.
Greinacher et al12 demonstrated a reduced incidence of
death, amputation, and new thromboembolic complica-
tions in patients who are treated with lepirudin as compared
with historical controls. They excluded patients undergoing
hemodialysis or hemofiltration because patients with
chronic renal insufficiency have reduced clearance of lep-
irudin and an increased anticoagulant effect. We included
patients with renal failure and treated them with reduced
doses of lepirudin with no complications.
Two (11%) of our patients had mild hemorrhagic
complications. Greinacher et al10 reported a 13.4% inci-
dence of major bleeding in their study of lepirudin and
HIT. The first patient had a single episode of epistaxis
that was easily controlled with compression. This patient
had multiple risk factors for a complication including
renal failure and multiple lepirudin treatments. The epi-
staxis occurred during the ninth hemodialysis procedure
with lepirudin when the patient’s dialysis catheter, which
was “locked” with approximately 10 mg of lepirudin,
was flushed. The second patient received lepirudin for
treatment of a pulmonary embolus. This patient had no
significant risk factors for complications such as multiple
lepirudin treatments or renal failure. The patient fell and
sustained a contusion with a hematoma of her right calf
that required operative drainage. No further bleeding
occurred. This patient had an aPPT ratio of 3.24,
indicating supratherapeutic anticoagulation. The calf
hematoma resulted from trauma to a patient undergoing
anticoagulation.
Lepirudin and the other thrombin inhibitors may
become the rapid-acting anticoagulant of choice, espe-
cially for patients with HAAbs. Thrombin inhibitors do
not cross-react with HAAbs as LMWHs (up to 80%) and
danaparoid (up to 20%) do. A patient’s HAAbs should be
tested for cross-reactivity to LMWH and danaparoid
before the patient receives either of them. In addition, the
thrombin inhibitors directly inhibit circulating and throm-
bus-bound thrombin unlike heparin, which requires
antithrombin to inhibit only circulating bound thrombin.
In conclusion, patients receiving lepirudin, as with any
other form of anticoagulation, must be closely monitored
to maintain a safe level of anticoagulation. Patients with
renal insufficiency and patients who have received lep-
irudin on multiple occasions should be closely monitored
and have lower doses of lepirudin to prevent excessive
anticoagulation. Care must be taken not to overdose with
lepirudin because no antidote is currently available. With
these provisions, lepirudin can be safely administered to
patients with HAAbs.
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Dr Patrick J. O’Hara (Cleveland, Ohio). If a patient needs to
have thrombolytic therapy in the presence of heparin antibodies,
how would you administer and monitor lepirudin in conjunction
with thrombolytic therapy?
Dr Junaid Mudaliar. In a patient with normal renal function
undergoing thrombolytic therapy, there is an increased rate of
bleeding with the use of lepirudin, and we usually halve the dose
to 0.2 mg/kg per hour and then halve the maintenance dose to
0.075 mg/kg per hour.
Dr Lazar Greenfield (Ann Arbor, Mich). This really is very
nice work and very helpful from a practical standpoint.
Presumably your customary short-term management was in
transition to oral anticoagulation.
Dr Mudaliar. Right.
Dr Greenfield. I am curious about a pregnant female in
whom you are unable to use Coumadin. What would your man-
agement approach be?
Dr Mudaliar. Fortunately, we have not run into that, but
there are papers in Europe that show use of subcutaneous lep-
irudin as well. They have used it for DVT prophylaxis and that
could be used as well for similar dosing for patients who require
long-term anticoagulation in that sense.
DISCUSSION
